Hua Medicine of Shanghai has dosed the first patient in a US Phase I/II trial of its oral type 2 diabetes candidate, dorzagliatin. Dorzagliatin is a small molecule fourth-gen glucokinase activator. It will be tested as a monotherapy and in combination with sitagliptin, Merck’s DPP-4 drug, Januvia. Hua believes dorzagliatin will control progression of the disease in some subsets of T2D patients. The company has over 600 T2D patients enrolled in China Phase III dorzagliatin clinical trials.
Source: China Biotoday
